Basilea Pharmaceutic Stock Earnings Reports

Basilea reported a strong 2025 with in-market Cresemba sales up 27% to USD 693m (12 months to Sept 2025), total revenue CHF 232.4m (+11% y/y), operating profit CHF 51.5m and net profit CHF 40.2m. Cash and equivalents rose to CHF 162.3m and net cash (after convertible bonds) tripled to CHF 86.9m. The company reduced convertible debt to CHF 76m and secured significant nondilutive R&D funding (contracts with BARDA and CARB‑X; over USD 430m awarded across agreements, >USD 100m committed). Commercially, Zevtera was launched in the U.S. in July 2025 with encouraging early formulary wins and expected stronger sales from Q2 2026; Cresemba remains the global market leader by value and continues to grow strongly, notably in Japan and China. Pipeline expansion: fosmanogepix (first‑in‑class antifungal) is in two Phase III studies with readouts expected in 2028; ceftibuten‑ledaborbactam (oral antibiotic for cUTI) was in‑licensed and is planned to enter Phase III in early 2027 with a readout in 2029. Basilea expects 2026 Cresemba/Zevtera‑related revenue around CHF 200m and total revenue growth ~10%; R&D spend is guided to increase ~20% to support two fosmanogepix Phase IIIs and other programs. Management projects cumulative cash flow of ~CHF 600m from Cresemba and Zevtera (2026–2030) and sees fosmanogepix and ceftibuten‑ledaborbactam as potential major future launches (management estimates peak sales approx. USD 1bn and USD 500m respectively). Expected impact of Cresemba loss of exclusivity: generics anticipated in U.S. from Q4 2027 and in Europe from H2 2028, with full visibility on revenue impact arriving in 2029; however, Cresemba should continue contributing cash beyond initial LOE. Overall, the company highlights a partner‑centric, low‑cost commercialization model, strong balance sheet, non‑dilutive funding runway, and a diversified pipeline positioned to drive mid‑ to long‑term growth while pursuing selective in‑licensing/acquisition opportunities.